Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
This formulation provides a balanced mixture of amino acids, dextrose, electrolytes, and calcium for parenteral nutrition. Amino acids serve as substrates for protein synthesis; dextrose provides caloric energy; electrolytes maintain acid-base and fluid balance; calcium is essential for bone mineralization and neuromuscular function.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
Parenteral nutrition for patients who cannot obtain adequate nutrition orally or enterally,Provision of calories, amino acids, electrolytes, and calcium in a single container
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
Dose is patient-specific based on caloric and electrolyte needs. Typical adult: 500-3000 m L intravenously over 24 hours; contains 25% dextrose (250 g/L) and 5% amino acids. Infuse via central line due to high osmolarity.
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Variable; amino acids have half-lives of minutes to hours; dextrose is rapidly cleared (half-life < 30 min). No terminal elimination half-life defined for mixture.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Amino acids undergo hepatic deamination and transamination; dextrose is metabolized via glycolysis and oxidative phosphorylation; electrolytes are regulated by renal and gastrointestinal mechanisms; calcium is distributed in bone and soft tissues.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
Renal: amino acids and dextrose metabolites are excreted renally; calcium and electrolytes are also cleared renally. Biliary/fecal: negligible.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Amino acids: minimal (10-20%); calcium: ~40% bound to albumin; dextrose: not bound.
Minimal (<10%) for most amino acids; not significantly protein-bound.
Amino acids: 0.5-1.0 L/kg (total body water); calcium: 0.2-0.3 L/kg; dextrose: 0.2 L/kg (extracellular fluid).
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
Intravenous: 100%.
Intravenous: 100%.
Contraindicated or dose-reduce in severe renal impairment (GFR <30 m L/min) due to risk of fluid overload and electrolyte imbalances. Monitor potassium, phosphorus, and magnesium closely.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
Use with caution in severe hepatic impairment (Child-Pugh class C). May worsen hepatic encephalopathy due to amino acid load; consider specialized formulations.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Dose individualized; typical infusion rate: 0.5-8 mg/kg/min dextrose equivalent. Calculate based on weight (kg), fluid requirements, and nutritional goals. Avoid in neonates with hyperbilirubinemia.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
Start at low end of dose range, monitor for fluid overload and electrolyte disturbances due to decreased renal function and comorbidities. Use cautious infusion rates.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
Not for use in patients with known hypersensitivity to any component. Contains aluminum that may be toxic with prolonged administration in renal impairment.
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
Risk of hyperglycemia, fluid overload, electrolyte disturbances, and aluminum toxicity,Monitor serum glucose, electrolytes, liver function, and acid-base status regularly,Use with caution in hepatic or renal impairment, heart failure, and hypercalcemia,Do not administer simultaneously with blood through same tubing
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Hypersensitivity to any component,Severe electrolyte disorders (e.g., hyperkalemia, hypercalcemia),Severe hepatic or renal impairment,Anuria, oliguria, or dialysis dependency
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
No direct food interactions as this product is administered intravenously. However, patients receiving parenteral nutrition should not eat or drink unless approved by the dietitian or doctor to avoid aspiration or metabolic imbalances. Enteral intake may affect blood glucose and electrolyte levels.
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
CLINIMIX E 5/25 contains dextrose, amino acids, electrolytes, and calcium. Dextrose at high concentrations may cause maternal hyperglycemia, potentially leading to fetal hyperinsulinemia and neonatal hypoglycemia, but no direct teratogenicity in first trimester. No specific teratogenic risks from amino acids or electrolytes at therapeutic doses. Calcium administration may affect fetal calcium homeostasis if maternal levels are markedly elevated. Overall, risk is related to underlying maternal condition rather than direct drug effect.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
CLINIMIX E 5/25 components are endogenous substances normally present in breast milk. Dextrose and amino acids infused are metabolized and do not accumulate in milk at significant levels. Electrolytes and calcium are tightly regulated. No M/P ratio available. Use is considered compatible with breastfeeding when clinically indicated.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
Pregnancy does not typically require dose adjustments for CLINIMIX E 5/25. However, adjustments may be needed for underlying metabolic conditions (e.g., gestational diabetes) or to avoid hyperglycemia. Calcium content should be monitored to avoid hypercalcemia. Individualize based on maternal glucose and electrolyte levels.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
This product is a dual-chamber bag containing amino acids 5%, dextrose 25%, and electrolytes including calcium. The 'Sulfite Free' designation is critical for patients with sulfite sensitivity. Calcium-containing PN must not be co-administered with ceftriaxone due to precipitation risk. Inline filter of 1.2 micron is recommended. Monitor serum calcium, phosphorus, and magnesium closely when adjusting PN. Hepatic function and triglycerides should be assessed if used for long-term nutrition.
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
This medication provides complete nutrition through your vein; it is not for oral use.,You may need blood tests to monitor your sugar, electrolyte levels, and liver function.,Report any signs of infection (redness, swelling, pain) at the IV site immediately.,Do not stop or change the infusion rate without consulting your doctor.,Tell your healthcare provider about any allergies, especially to sulfites.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by This formulation provides a balanced mixture of amino acids, dextrose, electrolytes, and calcium for parenteral nutrition. Amino acids serve as substrates for protein synthesis; dextrose provides caloric energy; electrolytes maintain acid-base and fluid balance; calcium is essential for bone mineralization and neuromuscular function.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is: Dose is patient-specific based on caloric and electrolyte needs. Typical adult: 500-3000 m L intravenously over 24 hours; contains 25% dextrose (250 g/L) and 5% amino acids. Infuse via central line due to high osmolarity.. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 5/25 contains dextrose, amino acids, electrolytes, and calcium. Dextrose at high concentrations may cause maternal hyperglycemia, potentially leading to fetal hyperinsul. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.